media – Page 12 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Mabwell Biotech’s innovative CDH17-targeted ADC drug 7MW4911 has been successfully administered to its first patient

November 25th, Mabwell Biotechnology announced on its official WeChat account that it has developed an innovative CDH17-targeting ADC drug.(Development code: 7MW4911) The first patient was recently dosed in a Phase I/II clinical trial for advanced solid tumors. Preclinical studies showed that 7MW4911 exhibited potent antitumor activity in CDX/PDX models of various gastrointestinal tumors; in multidrug-resistant models, its antitumor effect was significantly superior to MMAE/DXd ADCs, and it could reverse tumor progression after treatment with such ADCs, highlighting its advantages in the treatment of drug-resistant tumors. https://finance.eastmoney.com/a/202511253573547662.html
- Source: drugdu
- 83
- November 25, 2025
Approval Received for Marketing Authorization of Edoxaban Tosylate API

Jiuzhou PharmaceuticalThe announcement states that Zhejiang Jiuzhou Pharmaceutical Co., Ltd. received chemical raw materials from the National Medical Products Administration.The company recently received the Approval Notice for Marketing Authorization of its chemical active pharmaceutical ingredient, edoxaban tosylate. This oral anticoagulant is primarily used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as to treat or prevent deep vein thrombosis and pulmonary embolism. This approval indicates that the active pharmaceutical ingredient meets the relevant requirements for national drug registration and will further enrich the company’s product portfolio and enhance its market competitiveness. The above matters will not have a significant impact on the company’s performance in the short term. https://finance.eastmoney.com/a/202511243572990379.html
- Source: drugdu
- 71
- November 25, 2025
Breakthrough in Innovative Drug, “Twin-Engine” Strategy Forges New Landscape

Northeast Pharmaceutical recently stated in an interview with China Securities Journal that in recent years, the company has focused on innovation-driven strategies and deepening its core business, achieving significant results in R&D breakthroughs and business quality improvement. This has established a synergistic development pattern characterized by “breaking new ground in R&D innovation, stabilizing profitability in core business, and enhancing efficiency in asset operations.” Particularly against the backdrop of accelerating innovation and transformation in the pharmaceutical industry, the company has adopted a differentiated strategy of “consolidating the fundamental business through traditional operations while creating new growth drivers through innovative drug development.” This approach has not only safeguarded its profit baseline but also unlocked new growth potential. Recently, the company’s subsidiary, Dingcheng Peiyuan, received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration (NMPA) for its self-developed DCTY0801 Injection. Looking ahead, as the innovative drug pipeline advances and ...
- Source: drugdu
- 74
- November 25, 2025
sIPV vaccine granted approval for market, pentavalent combination vaccine granted approval for clinical trials

November 24 (NBD AI Express) — According to an update on China National Biotec Group (CNBG)’s official WeChat account, Wuhan Biological Products Institute, its subsidiary, has recently achieved significant progress in the field of pediatric vaccine development. The Sabin strain inactivated poliovirus vaccine (Vero cell) has received market approval from the National Medical Products Administration (NMPA) (Approval No.: S20250060). Simultaneously, the Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, and Haemophilus Influenzae Type b (Conjugate) Combined Vaccine has obtained clinical trial approval (Acceptance No.: CXSL2500756). Reference：https://finance.eastmoney.com/a/202511243572908132.html
- Source: drugdu
- 70
- November 25, 2025
Latest Developments in New Drugs for Kidney Disease

In the vast and complex field of chronic kidney disease, IgA nephropathy (IgAN) has long been considered a “silent corner.” However, with a deeper understanding of its pathogenesis and breakthroughs in treatment, this once-neglected disease area is now showing renewed vitality. 01 Changes in the Times The unique aspect of IgA nephropathy lies in its complex pathogenesis. Traditionally, it was considered an autoimmune disease, but recent studies have found that its pathogenesis involves multiple steps, including mucosal immune abnormalities, the production of galactose-deficient IgA1, the formation of autoantibodies, and the deposition of immune complexes, ultimately leading to kidney tissue damage through complement activation. The elucidation of this mechanism provides a clear direction for the development of targeted drugs. Current treatment strategies mainly focus on four pathways: (1) Mucosal immune regulation: targeting the initial stage of the pathogen immune response; (2) Inhibition of the endothelin-1 (ET-1) pathway: improving glomerular hemodynamics and ...
- Source: drugdu
- 72
- November 25, 2025
PD-1 + ADC, securing a major indication

Recently, Pfizer’s Padcev and Merck’s Keytruda (including the intravenous infusion version of Keytruda and the subcutaneous injection version of Keytruda Qlex) received early approval from the U.S. FDA for the perioperative treatment of adult patients with muscle invasive bladder cancer (MIBC). This regimen is suitable for MIBC patients who are ineligible for cisplatin-based chemotherapy, specifically consisting of neoadjuvant therapy (3 cycles) followed by adjuvant therapy (14 or 7 cycles). This is the first and only approved complete perioperative treatment regimen for MIBC patients who are ineligible for cisplatin. This approval is based on the results of the pivotal Keynote-905/EV-303 study. This study enrolled adult MIBC patients who were unsuitable for or actively refused cisplatin therapy and aimed to compare the efficacy of PD-1 inhibitor/ADC combination therapy plus surgery versus surgery alone. Merck presented the results of this study at this year’s ESCO annual meeting. After a median follow-up of 25.6 ...
- Source: drugdu
- 64
- November 25, 2025
CSPC Pharmaceutical Group Limited ‘s chemical 1-class new drug, a double-stranded small interfering RNA drug, has received approval for clinical trials from the FDA

On November 24th, CSPC (01093) released an announcement stating that the group’s independently developed chemical Class 1 new drug, the double-stranded small interfering RNA drug (SYH2061 injection), has been approved by the US Food and Drug Administration (FDA) and can now conduct clinical trials in the United States. Additionally, this product was approved by the China National Medical Products Administration in October 2025 to conduct clinical trials in China. SYH2061 injection is a siRNA drug that achieves liver-targeted delivery through the conjugation of acetylated galactosamine (GalNAc). It aims to target the complement protein C5 (C5) and effectively reduce its level. Preclinical studies have shown that this product outperforms other similar siRNA products in terms of drug activity and drug efficacy persistence, and has high clinical development value. It is suitable for the treatment of IgA nephropathy and other complement-mediated related diseases. https://finance.eastmoney.com/a/202511243573136076.html
- Source: drugdu
- 80
- November 25, 2025
Hinova Pharmaceuticals Inc.：The combination of HP518 tablets and anti-tumor drugs for the treatment of advanced prostate cancer has received the approval notice for clinical drug trials

People Finance News, November 24th: Hinova Pharmaceuticals Inc. (688302) announced on November 24th that recently, they received the “Drug Clinical Trial Approval Notice” issued by the Drug Evaluation Center of the National Medical Products Administration of China, approving the use of HP518 tablets in combination with anti-tumor drugs for the Phase IIB/II clinical trial for the treatment of advanced prostate cancer. As of now, HP518 tablets have been approved for clinical trials for advanced prostate cancer in China, Australia, and the United States respectively. Currently, there are no similar products approved for market launch domestically or internationally. HP518 is an oral PROTAC drug independently developed by the company based on its core technology platform for protein degradation targeting complexes. It is designed to target and degrade the androgen receptor and is intended to be used in combination with anti-tumor drugs for the treatment of advanced prostate cancer. https://finance.eastmoney.com/a/202511243573069661.html
- Source: drugdu
- 64
- November 25, 2025
World Health Expo Dubai

Organiser：Informa Group Time：February 9 -12, 2026 Address：Sheik Zayed Road Convention Gate Dubai UAE – United Arab Emirates Exhibition hall：Dubai World Trade Centre Product range: Medical Devices and Instrumentation Equipment Medical electronic instruments, medical ultrasonic instruments, medical X-ray equipment, medical optical instruments, clinical laboratory analysis instruments, dental equipment and materials, operating room, emergency room, and consultation room equipment and appliances, disposable medical supplies, medical dressings and hygiene materials, various surgical instruments, medical health care equipment and supplies, traditional Chinese medical instruments and rehabilitation equipment, blood dialysis equipment, anesthesia and respiratory equipment, etc. Home Health Care Products and Small-scale Health Care Instruments: Home health care products, small-scale home diagnostic, monitoring, and treatment instruments, rehabilitation/physical therapy instruments and supplies, electronic medical instruments, dental tools, hospital office supplies, sports medicine supplies Active Pharmaceutical Ingredients, Traditional Chinese Medicines, and Pharmaceutical Health Care Products Treatment, rehabilitation, and health care drugs and supplies with characteristics of ...
- Source: drugdu
- 92
- November 25, 2025
Walvax Biotechnology announces that the clinical trial application for its Varicella Attenuated Live Vaccine has been accepted

On November 21, Walvax Biotechnology (300142) announced that the clinical trial application for its Varicella Attenuated Live Vaccine has been accepted by the National Medical Products Administration, with the acceptance number CXSL2500991. The application was jointly developed by the company and its subsidiary. The product is named Varicella Attenuated Live Vaccine and is classified as a preventive biological product under Category 3.3. The vaccine is produced using an attenuated strain of the varicella-zoster virus and aims to stimulate the body’s immune response against the virus to prevent varicella. The announcement noted that although the clinical trial application for this vaccine has been accepted, it must still be approved by the Center for Drug Evaluation of the National Medical Products Administration after technical review before clinical trials can proceed. The outcome of the review and approval process remains uncertain. This acceptance is not expected to have a significant impact on the ...
- Source: drugdu
- 98
- November 24, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.